Metabolic
Eloralintide
Also called LY3841136
InjectableEvidence BOnce a week
per administration
Some human use
It has been used in people, but no trial has settled how much or how often.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 1.67mg/mL
- Volume per draw
- 0.6mL
- Units to dial
- 60
- Doses per cartridge
- 5
Vial label
Copy this into your label printer.
Published research contexts for Eloralintide describe 1–3 mg per administration. Descriptive only, not a recommendation.
Consistent with once-weekly administration; phase 1 pharmacokinetics are not established in publication.
An amylin receptor agonist studied for weight reduction in phase 1 research only. No dose-ranging publication fixes a subcutaneous schedule, so no schedule table is shown.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Eloralintide (LY3841136) phase 1 program (Eli Lilly)Early-phase subcutaneous amylin-agonist dosing; no dose-ranging trial has been published.